Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.